IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
April 30, 2024 06:05 ET
|
IN8bio, Inc
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
April 30, 2024 06:05 ET
|
MannKind
MannKind announced it will proceed with a Phase 1 study of nintedanib DPI (MNKD-201) for pulmonary fibrotic diseases including IPF.
Iovance Biotherapeutics to Present at Upcoming Conferences
April 30, 2024 06:01 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor...
Oaktree Specialty Lending Corporation Announces Permanent Base Management Fee Reduction
April 30, 2024 06:01 ET
|
Oaktree Specialty Lending Corporation
LOS ANGELES, April 30, 2024 (GLOBE NEWSWIRE) -- Oaktree Specialty Lending Corporation (NASDAQ:OCSL) (“OCSL” or the “Company”) today announced a permanent reduction in its base management fee....
H World Group Limited Announces Completion of the Put Right Offer for Its 3.00% Convertible Senior Notes due 2026
April 30, 2024 06:00 ET
|
H World Group Limited
SHANGHAI, China, April 30, 2024 (GLOBE NEWSWIRE) -- H World Group Limited (Nasdaq: HTHT and HKEx: 1179, the “Company” or “H World”), a key player in the global hotel industry, today announced that...
Oaktree Specialty Lending Corporation Announces Second Fiscal Quarter 2024 Financial Results and Declares Quarterly Distribution of $0.55 Per Share
April 30, 2024 06:00 ET
|
Oaktree Specialty Lending Corporation
Announces Permanent Management Fee Reduction LOS ANGELES, April 30, 2024 (GLOBE NEWSWIRE) -- Oaktree Specialty Lending Corporation (NASDAQ: OCSL) (“Oaktree Specialty Lending” or the “Company”), a...
Swvl Records $3.1m Net Profit, 13% Net Margin, and an Eightfold Growth in Gross Profit
April 30, 2024 06:00 ET
|
SWVL Global FZE
8x Gross Profit growth year on year to $4.1 million Achieved cash flow positivity, with self-funded growth Profitable growth drove earnings per share from continuing operations to $0.61 ...
Zymeworks Announces Participation in Upcoming Investor Conferences
April 30, 2024 06:00 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Gentherm Reports 2024 First Quarter Results
April 30, 2024 06:00 ET
|
Gentherm Inc
Achieved 86% Year over Year Growth in Net IncomeSecured $530M of Automotive New Business AwardsReaffirms 2024 Guidance NORTHVILLE, Mich., April 30, 2024 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ:THRM),...
Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access
April 30, 2024 05:45 ET
|
Cingulate Inc.
KANSAS CITY, Kan., April 30, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...